HC Deb 17 March 1980 vol 981 cc42-3W
Mr. Carter-Jones

asked the Secretary of State for Social Services if he will list the members and terms of reference of the committee on the review of medicines; what are the aims and objectives of the committee; what is the committee's programme of work; and if he will make a statement.

Sir George Young

The present membership of the committee is as follows:

  • Professor O. L. Wade, MD, FRCP, FRCPI, (Chairman)—Dean of the Faculty of Medicine and Dentistry, Birmingham University.
  • Dr. Barbara M. Ansell, MD, FRCP—Consultant Physician (Rheumatology) MRC Rheumatism Research Unit, Canadian Red Cross Memorial Hospital, Taplow, Bucks.
  • Dr. T. B. Binns, FRCP, DCH—Department of Pharmacology and Therapeutics, London Hospital Medical College.
  • Prof. G. Born, FRS, MA, MB, ChB—Department of Pharmacology, University of London, Kings College, Strand.
  • Prof. J. E. Carless, BPharm, MSc, PhD, FPS—Professor of Pharmaceutics, School of Pharmacy, London.
  • Prof. P. Curzen, BSc, MD, FRCOG—Professor of Obstetrics and Gynaecology, Westminster Medical School, University of London.
  • Dr. D. G. Davey, OBE, MSc, PhD, F Inst Biol—Research Director in Pharmaceutical Industry (retired).
  • Dr. Jose Day, MB, BS, MRCGP—General Practitioner.
  • Dr. F. Fletcher Hyde, BSc, FNIMH—Director Research, National Institute Medical Herbalists; Chairman, British Herbal Pharmacopoeia.
  • Prof. M. R. P. Hall, MB, BCh, FRCP, FRCP (Ed.)—Professor of Geriatric Medicine, Southampton University
  • Dr. F. Dudley Hart, MD, FRCP—Consultant Physician, Westminster Hospital, London
  • Mr. C. R. Hitchings, BPharm, MSc, MPS—Area Pharmaceutical Officer, Camden and Islington.Area Health Authority (Teaching)
  • Mr. W. G. Hollis, FPS—Former Director, Proprietary Association of Great Britain
  • Dr. R. C. Humphreys, MB, CHB, MD,.FRCGP, DOBST—General Practitioner
    • 43
  • Prof. M. H. Lader, BSc, PhD, MD, DPm, FRCP, Psych—Professor in Clinical Psycho-pharmacology, University of London
  • Prof. M. J. S. Langman, BSc, MD, FRCP—Professor of Therapeutics, Nottingham University Medical School
  • Prof. D. H Lawson, MD, FRCP (Ed)—Consultant Physician, Glasgow Royal Infirmary
  • Prof. W. Linford Rees, CBE, DSc, PRCPsych, MD, FRCP, DPM, FACP (Hon)—Professor of Psychiatry, University of London and St. Bartholomew's Hospital, London
  • Prof. F. W. O'Grady, TD, MD, MSc, FRC, Path—Professor of Microbiology, University of Nottingham
  • Mr L. Priest, MSc, B.Pharm, FPS—General Practice Pharmacist
  • Dr. A. Richens, BSc, PhD, MB, BS, MRCP—Consultant Clinical Pharmacologist, Royal Hospital for Nervous Diseases, London
  • Dr. B. A. Sellick, MB. BS, FFARCS—Consultant Anaesthetist, Middlesex Hospital and Royal Masonic Hospital, London
  • Prof. W. Walker, MA, MB, FRCP, FRCP (Ed)—Regius Professor of Materia Medica, Department of Therapeutics and Clinical Pharmacology, University of Aberdeen
  • Dr. G. Watkinson, MD, BS, FRCP, FRCP (Glas)—Consultant Physician and Gastro-Enterologist, Western Infirmary, Gartnavel General Hospital and Southern General Hospital, Glasgow.

The committee's terms of reference are to consider and give advice on the safety, quality and efficacy, in relation to human use, of any substance or article to which any provision of the Medicines Act is applicable in connection with the review by the licensing authority of the safety, quality and efficacy of substances or articles in respect of which product licences granted under part II of the Act are in force.

The committee is at present engaged in a systematic review of psychotropic drugs and immunological agents. Other products, irrespective of their uses, are referred to the committee for urgent consideration if there is apparent hazard in use. My hon. Friend hopes to make an announcement later this year about the next categories of drugs which the committee will be asked to review.